
    
      This is a study involving a 12 week treatment phase followed by a 6 month extension phase.
      During the treatment phase subjects receive FLUTIFORM® or Seretide®. In the extension phase
      all subjects receive FLUTIFORM®. Efficacy will be assessed by lung function tests and asthma
      symptoms, sleep disturbance. Safety will be assessed by adverse events, vital signs, lab
      tests and ECGs.
    
  